Endo International PLC (ENDP) PT Lowered to $25.00 at Citigroup Inc.
Endo International PLC (NASDAQ:ENDP) had its target price lowered by Citigroup Inc. from $40.00 to $25.00 in a research note issued to investors on Friday. Citigroup Inc. currently has a buy rating on the stock.
ENDP has been the topic of several other reports. Vetr upgraded Endo International PLC from a hold rating to a buy rating and set a $21.95 target price on the stock in a research note on Thursday, August 25th. Leerink Swann reaffirmed a market perform rating and set a $23.00 price target on shares of Endo International PLC in a research report on Wednesday, June 29th. Morgan Stanley set a $16.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Thursday, September 8th. JMP Securities reaffirmed a buy rating on shares of Endo International PLC in a research report on Wednesday, June 29th. Finally, Mizuho raised Endo International PLC from an underperform rating to a neutral rating and lifted their price target for the stock from $13.00 to $16.00 in a research report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $39.32.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 20.29 on Friday. The company’s 50 day moving average price is $20.98 and its 200 day moving average price is $22.03. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $77.21. The stock’s market cap is $4.52 billion.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The firm had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. During the same period in the previous year, the business earned $1.08 EPS. The firm’s revenue for the quarter was up 25.3% on a year-over-year basis. On average, analysts anticipate that Endo International PLC will post $4.56 earnings per share for the current year.
Several large investors have recently bought and sold shares of the stock. Nuveen Asset Management LLC raised its stake in Endo International PLC by 192.7% in the first quarter. Nuveen Asset Management LLC now owns 62,099 shares of the company’s stock worth $1,748,000 after buying an additional 40,883 shares during the period. Sabby Management LLC acquired a new position in Endo International PLC during the first quarter worth approximately $1,408,000. Geode Capital Management LLC boosted its position in Endo International PLC by 0.9% in the first quarter. Geode Capital Management LLC now owns 1,759,167 shares of the company’s stock worth $49,422,000 after buying an additional 15,173 shares in the last quarter. Riverhead Capital Management LLC boosted its position in Endo International PLC by 5.5% in the first quarter. Riverhead Capital Management LLC now owns 32,435 shares of the company’s stock worth $913,000 after buying an additional 1,694 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Endo International PLC during the first quarter worth approximately $139,000. Institutional investors and hedge funds own 96.64% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.